awmsg logo



buprenorphine (Buvidal®)


Reference No. 3977

Publication date:
18/09/2019


Appraisal information

buprenorphine (Buvidal®) 8 mg solution for injection
buprenorphine (Buvidal®) 16 mg solution for injection
buprenorphine (Buvidal®) 24 mg solution for injection
buprenorphine (Buvidal®) 32 mg solution for injection
buprenorphine (Buvidal®) 64 mg solution for injection
buprenorphine (Buvidal®) 128 mg solution fo injection
buprenorphine (Buvidal®) 96 mg solution for injection


Company: Camurus AB
BNF category: Central nervous system
NMG meeting date: 12/06/2019
AWMSG meeting date: 11/09/2019
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1119
Ratification by Welsh Government: 16/09/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Buprenorphine (Buvidal®) is recommended as an option for use within NHS Wales for the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download